Erytra Blood Group Analyser and Kode Technology testing of SARS-CoV-2 antibodies among convalescent patients and vaccinated individuals
Erytra Blood Group Analyser and Kode Technology testing of SARS-CoV-2 antibodies among convalescent patients and vaccinated individuals
Summary Surveillance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic requires tests to monitor antibody formation and prevalence. We detected SARS-CoV-2 antibodies using red cells coated by Kode technology with short peptides derived from the SARS-CoV-2 spike protein. Such modified red cells, called C19-kodecytes, can be used as reagent cells in any manual or automated column agglutination assay. We investigated the presence of SARS-CoV-2 antibodies in 130 samples from COVID-19 convalescent plasma donors using standard manual technique, two FDA authorized ELISA assays and a virus neutralisation assay. The sensitivity of the C19-kodecyte assay was 88%, comparable to the anti-SP and anti-NCP ELISAs (86% and 83%) and the virus neutralisation assay (88%). The specificity of the C19-kodecyte assay was 90% (anti-SP 100% and anti-NCP 97%). Likewise, 231 samples from 73 vaccinated individuals were tested with an automated analyser and we monitored the appearance and persistence of SARS-CoV-2 antibodies. The C19-kodecyte assay is a robust tool for SARS-CoV-2 antibody detection. Automated blood group analyser use enables large-scale SARS-CoV-2 antibody testing for vaccination monitoring in population surveys.
Schrezenmeier Hubert、Henry Stephen M、Flegel Willy A、Kaiser Sabine、Ludwig Carolin、Srivastava Kshitij、Bovin Nicolai V、Tsamadou Chrysanthi、Jahrsd?rfer Bernd、Weinstock Christof
German Red Cross Blood Service Baden-W¨1rttemberg ¨C Hessen, Ulm, Institute of Clinical Transfusion Medicine and Immunogenetics, Ulm, and Department of Transfusion Medicine, Ulm UniversityCentre for Kode Technology Innovation, School of Engineering, Computer and Mathematical Sciences, Faculty of Design and Creative Technologies, Auckland, University of TechnologyDepartment of Transfusion Medicine, NIH Clinical Center, National Institutes of HealthGerman Red Cross Blood Service Baden-W¨1rttemberg ¨C Hessen, Ulm, Institute of Clinical Transfusion Medicine and Immunogenetics, Ulm, and Department of Transfusion Medicine, Ulm UniversityGerman Red Cross Blood Service Baden-W¨1rttemberg ¨C Hessen, Ulm, Institute of Clinical Transfusion Medicine and Immunogenetics, Ulm, and Department of Transfusion Medicine, Ulm UniversityDepartment of Transfusion Medicine, NIH Clinical Center, National Institutes of HealthCentre for Kode Technology Innovation, School of Engineering, Computer and Mathematical Sciences, Faculty of Design and Creative Technologies, Auckland, University of TechnologyGerman Red Cross Blood Service Baden-W¨1rttemberg ¨C Hessen, Ulm, Institute of Clinical Transfusion Medicine and Immunogenetics, Ulm, and Department of Transfusion Medicine, Ulm UniversityGerman Red Cross Blood Service Baden-W¨1rttemberg ¨C Hessen, Ulm, Institute of Clinical Transfusion Medicine and Immunogenetics, Ulm, and Department of Transfusion Medicine, Ulm UniversityGerman Red Cross Blood Service Baden-W¨1rttemberg ¨C Hessen, Ulm, Institute of Clinical Transfusion Medicine and Immunogenetics, Ulm, and Department of Transfusion Medicine, Ulm University
医学研究方法预防医学生物科学研究方法、生物科学研究技术
red cellsC19-kodecytesSARS-CoV-2COVID-19antibody testingvaccination monitoringantiglobulin test
Schrezenmeier Hubert,Henry Stephen M,Flegel Willy A,Kaiser Sabine,Ludwig Carolin,Srivastava Kshitij,Bovin Nicolai V,Tsamadou Chrysanthi,Jahrsd?rfer Bernd,Weinstock Christof.Erytra Blood Group Analyser and Kode Technology testing of SARS-CoV-2 antibodies among convalescent patients and vaccinated individuals[EB/OL].(2025-03-28)[2025-06-07].https://www.medrxiv.org/content/10.1101/2021.08.26.21262219.点此复制
评论